UNSPSC 51293101: Adafenoxate

This classification denotes an antidepressant agent with the molecular formula C20H26ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B8VQU4C05J, chemically known as 2-(1-tricyclo(3.3.1.1(3,7))decylamino)ethyl (4-chlorphenoxy)acetat but generally known as adafenoxate, which bears US NIH Compound Identifier 64517. European Medicines Agency schedules Adafenoxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05259MIG.

UNSPSC 51293101 Adafenoxate (Commodity) encompasses pharmaceutical products procured by state and local health agencies, though recent opportunities show state and local governments buying naloxone, over-the-counter medications, and generic pharmaceuticals through competitive bidding and cooperative purchasing arrangements. The code's nominal scope—a specific pharmaceutical active ingredient—does not align with the actual procurement activity, which centers on broad-based pharmaceutical supply, drug deactivation systems, and pharmacy benefit program management rather than adafenoxate specifically. Issuing bodies soliciting under or near this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These jurisdictions procure through IFBs for direct pharmaceutical goods, RFIs for pharmacy program design and vendor capabilities, and RFPs for multi-vendor supply agreements. Vendors must meet federal compliance requirements including cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, FDA approval, E-Verify employment verification, and often carry commercial general liability insurance at $5,000,000 per occurrence or higher.

Recent activity spans Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS in June 2026 (response due July 26, 2023—a date discrepancy in the source) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, potentially FEMA-funded. Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for direct contracting outside traditional pharmacy benefit manager channels. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 (response due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across state and local facilities including Oregon, requiring NDC codes, cGMP compliance, and pricing through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with evaluation weighted 75 percent on price competitiveness. The code shows little thematic alignment with recent state and local pharmaceutical procurement; vendors pursuing activity in this space should track broader pharmaceutical supply, not the adafenoxate commodity specifically.